📢 #EVENT - Frédéric Fasano, Chief Strategy & Corporate Development Officer at MaaT Pharma, will deliver a keynote presentation at the 11th Microbiome R&D & Business Collaboration Congress – Asia, organized by Global Engage (April 29–30, 2026, Singapore).
🎤 April 30, 9:25–10:00 AM local time
📢 #EVENT – Meet Eric Soyer, Chief Financial Officer at MaaT Pharma, and Guilhaume Debroas, Head of Corporate Development, during the Life Sciences Conference by Van Lanschot Kempen, in Amsterdam on April 15-16.
@vanlanschotkempen.bsky.social
#LifeSciences #Biotech #Investors #Innovation #Kempen
📅 #Event – Eric Soyer, Chief Financial Officer at MaaT Pharma, will attend the Investor Access event on April 8–9, 2026, in Paris, France.
👉 We look forward to engaging with investors and sharing MaaT Pharma’s vision and progress in hemato-oncology!
#InvestorAccess #Microbiome #Oncology #Finance
📰 #Media – We’re pleased to share that the real‑world CHRONOS study, the largest evaluation to date of third‑line therapy in GI-aGVHD, has just been featured in CancerNetwork.
👉 Read the article here: www.cancernetwork.com/view/third-l...
#Microbiome #Microbiotherapy #aGvHD #Hematology #Oncology
📰 #PressRelease – MaaT Pharma announces publication of retrospective data from CHRONOS, a large real-world third-line GI-aGvHD study (n=59), in Bone Marrow Transplantation Journal.
🔗 Read the full press release: www.maatpharma.com/april-1st-20...
#Biotech #Hematology #aGvHD #GvHD #Microbiome
📰 [#PressRelease] – MaaT Pharma Announces 2025 Annual Results and Provides Business Updates
2025 was a year of strong progress for MaaT Pharma as we advanced our oncology platform and prepared for key milestones ahead.
👉 Read the full press release: www.maatpharma.com/march-31-202...
📰 #Media – Proud to be featured in Targeted Oncology highlighting the final Phase 3 ARES results of MaaT013, presented yesterday at EBMT by Prof. Florent Malard.
👉 Read the full article: www.targetedonc.com/view/microbi...
@theebmt.bsky.social
#Microbiome #Microbiotherapy #aGvHD #Hematology
📰 [PressRelease] – MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the EBMT.
👉 Read the press release: www.maatpharma.com/march-23-202...
@theebmt.bsky.social
#Cancer #Hematology #AlloHCT #Microbiome #EBMT26
📢 MaaT Pharma will present at the ISL-FD Conference 2026 (March 24–27).
On Mar 27, Sophie Declomesnil will discuss freeze-drying preservation of faecal microbiotherapies and ensuring comparability between frozen and lyophilized formulations.
👉 More information: islyophilization.org/homepage/con...
📰 [#PressRelease] - MaaT Pharma to Present Four Abstracts at the 52nd EBMT Annual Meeting and to Highlight the Clinigen Hosted Industry Symposium on Acute GvHD Management
👉 shorturl.at/lHH12
📰 Proud to be featured in Nature Reviews Cancer
The article highlights the growing recognition of microbiota-centered interventions as a promising avenue to improve outcomes in acute GvHD and allo-HCT.
👉 Read the full article: www.nature.com/articles/s41...
@nature.com @natrevcancer.nature.com
📢 #GvHDDay | Spotlight on unmet needs in aGvHD
Following yesterday’s expert insights, we’re sharing an infographic highlighting the severity and burden of this rare, life-threatening complication following allogeneic stem cell transplantation.
👉 Full infographic: www.maatpharma.com/wp-content/u...
📢 #GvHDDay | Raising awareness about aGvHD
As we approach this special day, we share a video of Prof. Malard highlighting the severity of aGvHD after allo‑HSCT and the major challenges we still face in managing this life‑threatening complication.
👉 Full video: www.maatpharma.com/healthcare-p...
📰 Proud to be featured in Nature Biotechnology
In this article, MaaT Pharma is highlighted for its approach to restoring gut ecosystem function and advancing microbiome-based therapies across hematology and oncology.
👉 Full article: www.nature.com/articles/s41...
@nature.com @natbiotech.nature.com
📢 [#JobOpening] – Join MaaT Pharma as 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗕𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝘀 (𝗠/𝗙)!
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
🗓️ Permanent position, available immediately
📍 Lyon, France
🎗️ #𝗪𝗼𝗿𝗹𝗱𝗖𝗮𝗻𝗰𝗲𝗿𝗗𝗮𝘆 𝟮𝟬𝟮𝟲 - In hemato-oncology, every step matters.
At MaaT Pharma, we develop microbiome-based therapies to support patients with blood cancers, aiming to strengthen immunity and improve outcomes, while honoring the dedication of healthcare teams fighting these diseases.
📰 – We’re proud to see MaaT Pharma featured in the annual Biotech Round-Up by Les Echos Investir.
Many thanks to Anne Barloutaud for including us in the “Biotechs to follow in 2026”.
👉 Full article: investir.lesechos.fr/conseils-bou...
@lesechosfr.bsky.social
📰 Hervé Affagard, CEO de MaaT Pharma, à l’honneur dans le Journal des Biotechs de Boursorama !
Un grand merci à Laurent Grassin pour la mise en lumière de notre trajectoire et des prochains jalons pour 2026.
👉 Revoir l’interview : www.boursorama.com/videos/actua...
@boursorama.bsky.social
📰 MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis.
👉 Read the press release: www.maatpharma.com/january-20-2...
📢 Join MaaT Pharma as a Data Engineer (M/F)!
📩 Interested? Send your resume and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
#DataEngineer #BigData #Biotech #DataScience #Microbiome #HealthcareInnovation
📢 [EVENT] – Join Guilhaume Deboras, Head of Corporate Development of MaaT Pharma, at the 10th Annual @Microbiome Movement Summit Europe, taking place on January 28-29 in London, UK.
👉 Learn more: microbiome-europe.com
#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
📰 MaaT Pharma featured in PharmaBoardroom!
Hervé Affagard, CEO and Co-Founder of MaaT Pharma, discusses the Company’s journey, scientific vision and path toward a potential first approval.
👉 Read the full interview here: pharmaboardroom.com/interviews/h...
#aGvHD #Oncology #Hematology #Microbiome
At #ASH2025, Prof. Florent Malard shared Phase III ARES results with #VJHEMONC, highlighting Xervyteg® (MaaT013) in aGvHD: 62% GI response, 64% ORR and 54% 1-year OS.
👉 Full interview: www.vjhemonc.com/video/xm1_uw...
@ash.hematology.org @vjhemonc.bsky.social
🎥 Prof. Mohamad Mohty, MD, PhD, in an exclusive interview with VJ HemOnc at #ASH2025, shared #GvHD advances and Xervyteg® (MaaT013) with a 54% one-year survival rate.
👉 Full interview: www.vjhemonc.com/video/uz21rt...
@ash.hematology.org @vjhemonc.bsky.social
🎥 During #ASH2025 Annual Meeting, Hervé Affagard, CEO and co-founder of MaaT Pharma, was interviewed by Brad Loncar for BiotechTV.
🙏 Many thanks for this insightful discussion and for spotlighting our work.
👉 Watch the full interview: www.biotechtv.com/post/maat-ph...
@biotechtv.bsky.social
📰 [Press Release] - Live from ASH 2025: MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
Read the full press release here: www.maatpharma.com/december-8-2...
#ASH2025 #aGvHD #Cancer
📅 Heading to #ASH2025!
Meet MaaT Pharma’s Acting CSO Sheri Simmons & CEO Hervé Affagard in Orlando, Dec 6–9.
We’re also excited for Prof. Florent Malard to present Phase 3 ARES trial results on Xervyteg® (MaaT013) in SR GI-aGvHD patients.
👇 Presentation details below.
✨ MaaT Pharma showcases its expertise at the 28th Congress of the French Cytometry Association (AFC - Association Française de cytométrie)!
Chloé Badonnel showcased MaaT Pharma’s CMC expertise, presenting MaaT034’s manufacturing and a new flow cytometry method to assess bacterial activity. 👏
📢 #Internship – Join MaaT Pharma as a Data Engineer Intern (M/F)!
📩 Interested? Send your CV and a short motivation email to careers@maat-pharma.com to apply now!
🔬 Full job description: www.maatpharma.com/wp-content/u...
📅 6-month internship – starting early 2026
📍 Lyon, France
#DataEngineering
🎥 MaaT Pharma sur #BFMBusiness ! Ce matin, Hervé Affagard, CEO et cofondateur de MaaT Pharma, était l’invité Laure Closier dans la rubrique #FrenchTech de Good Morning Business.
👉 Revoir l’interview ici : www.bfmtv.com/economie/rep...
@bfmbusiness.bsky.social
